Avant Completes Acquisitions of Amarantus, Theranostics Health

We’re here for the entrepreneurs

Avant Completes Acquisitions of Amarantus

and Theranostics Health

Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health.

In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus’ research-use-only assays for multiple sclerosis and Alzheimer’s disease with Avant’s upcoming microarray-based ovarian cancer diagnostic OvaDx.

Under the terms of that arrangement, Avant acquired all outstanding shares of Amarantus in exchange for 80 million shares of Avant stock, with additional shares to be issued upon certain undisclosed milestones.

Read the story at GenomeWeb

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    14:00-15:30
    08/31/2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter